Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
69,596,826
-
Total 13F shares
-
28,212,747
-
Share change
-
-1,971,427
-
Total reported value
-
$316,546,978
-
Put/Call ratio
-
142%
-
Price per share
-
$11.22
-
Number of holders
-
83
-
Value change
-
-$21,720,545
-
Number of buys
-
40
-
Number of sells
-
37
Institutional Holders of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) as of Q4 2022
As of 31 Dec 2022,
Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) was held by
83 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,212,747 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Invesco Ltd., Avidity Partners Management LP, Ensign Peak Advisors, Inc, BlackRock Inc., Abingworth LLP, 683 Capital Management, LLC, VANGUARD GROUP INC, and GW&K Investment Management, LLC.
This page lists
83
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.